U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT07546695) titled 'Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11/MACRONAC Study' on April 16.
Brief Summary: In this multicenter retrospective cohort study the aim is to determine the safety of omission of axillary lymph node dissection in patients with TNBC and HER2+ tumors with residual macrometastases (in the SLN/TAD/TAS or MARI node) after NAC.
Study Start Date: Feb. 01
Study Type: OBSERVATIONAL
Condition:
Breast Cancer
Intervention:
OTHER: Data Collection from medical records of from an already existing database "ONCOL...